First-year discontinuation commonly reflects high out-of-pocket costs coupled with expectations that weight loss will be ...
In the announcement, FDA Commissioner Mackary said, “Bayesian methodologies help address two of the biggest problems of drug ...
In today's Pharmaceutical Executive Daily, the Trump administration delays its appeal of the federal ruling blocking RFK ...
Merck is partnering with Infinimmune in a deal worth up to $838 million to leverage AI-driven antibody discovery. Do you know ...
MFN policies are likely to impact more than pricing, and drug companies may alter drug launch plans in the future.
When the bubble bursts, the tools that survive will not be the ones that generated the best demos. They will be the ones ...
The deal continues Shionogi’s streak of acquisitions to begin 2026, as the company began the year acquiring $2.1 Billion ViiV ...
Agencies such as FDA, Centers for Disease Control (CDC), Health and Human Services (HHS), and The Center for Drug Evaluation ...
The Trump administration has also pushed back against Covid vaccine recommendations, and the FDA toughened its requirements ...
In today’s Pharmaceutical Executive Daily, leadership turnover continues across key federal health agencies under the Trump ...
Soley Therapeutics’ co-founder and CEO Yerem Yeghiazarians, MD, spoke with Pharmaceutical Executive about the unique approach ...
The U.S. pharmaceutical market is at a critical inflection point in early 2026. For decades, the industry has operated within a framework that, while fostering significant innovation, has also ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results